Results
Twenty-nine respondents participated in the survey: pediatric
hematologists/oncologists (n= 15), pediatric cardiologists (n= 10),
dermatologists (n = 2), an ophthalmologist (n = 1), and a neonatologist
(n = 1). Most respondents use generic propranolol in infants with
growing IH of the head and neck, with a goal dose of 2 mg/kg/day, until
approximately one year of age. A variety of management strategies were
documented including which patients should be treated, optimal dose and
duration of therapy, how patients should be monitored, which patients
should get additional work up, how propranolol should best be
discontinued, and how often to see patients in follow-up.